deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT03546361

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

A Phase I Trial of Intratumoral Administration of CCL21-Gene Modified Dendritic Cell (Ad-CCL21-DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC

Sponsor: California Institute for Regenerative Medicine (CIRM)

Conditions Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8
Interventions Autologous Dendritic Cell-Adenovirus CCL21 Vaccine Pembrolizumab
Updated 17 times since 2018 Last updated: Jan 10, 2025 Started: Jul 8, 2019 Primary completion: Jan 11, 2026 Completion: Jan 11, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Lung Non-Small Cell Carcinoma and Stage IV Lung Cancer AJCC v8, this trial is ongoing. The trial is conducted by California Institute for Regenerative Medicine (CIRM) and has accumulated 17 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jul 2018 – ~Nov 2018 · 4 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Dec 2019 · 9 months · monthly snapshot~Dec 2019 – ~Aug 2020 · 8 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Jun 2022 · 9 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~May 2023 · 8 months · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Jun 2024 · 11 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – present · 18 months · monthly snapshot

Change History

17 versions recorded

  1. Feb 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Jul 2023 — Jun 2024 [monthly]

    Recruiting PHASE1

▶ Show 12 earlier versions

  1. May 2023 — Jul 2023 [monthly]

    Recruiting PHASE1

  2. Sep 2022 — May 2023 [monthly]

    Recruiting PHASE1

  3. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  4. Sep 2021 — Jun 2022 [monthly]

    Recruiting PHASE1

  5. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  6. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  7. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  8. Dec 2019 — Aug 2020 [monthly]

    Recruiting PHASE1

  9. Mar 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  10. Feb 2019 — Mar 2019 [monthly]

    Not Yet Recruiting PHASE1

  11. Nov 2018 — Feb 2019 [monthly]

    Not Yet Recruiting PHASE1

  12. Jul 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • California Institute for Regenerative Medicine (CIRM)
  • Jonsson Comprehensive Cancer Center
  • LUNGevity Foundation
  • Merck Sharp & Dohme LLC
  • National Cancer Institute (NCI)
Data source: Jonsson Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations